Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 28 October 2019. Angela Culhane.

Executive Summary

The combined market for prostate cancer diagnostics and minimally invasive treatments is expected to reach $1460m in the next five years, according to a recent Meddevicetracker report. See what UK chief executive of charity Prostate Cancer UK, Angela Culhane, said about it here.

“We need new tests and improvements at each stage of diagnosis, including a more specific test that could follow the PSA test to rule out some false positives before a mpMRI scan. This will most likely be an advanced type of blood test that looks for several markers of cancer, including proteins and genes that are linked to a high risk of cancer." – Angela Culhane, chief executive, Prostate Cancer UK

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts